A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is a devastating, genetic neurodegenerative disease caused by a tri-nucleotide expansion in exon 1 of the huntingtin gene. HD is clinically characterized by chorea, emotional and psychiatric disturbances and cognitive deficits with later symptoms including rigidity and dementia. Pathologically, the cortico-striatal pathway is severely dysfunctional as reflected by striatal and cortical atrophy in late-stage disease. Brain-derived neurotrophic factor (BDNF) is a neuroprotective, secreted protein that binds with high affinity to the extracellular domain of the tropomyosin-receptor kinase B (TrkB) receptor promoting neuronal cell survival by activating the receptor and down-stream signaling proteins. Reduced cortical BDNF production and transport to the striatum have been implicated in HD pathogenesis; the ability to enhance TrkB signaling using a BDNF mimetic might be beneficial in disease progression, so we explored this as a therapeutic strategy for HD. Using recombinant and native assay formats, we report here the evaluation of TrkB antibodies and a panel of reported small molecule TrkB agonists, and identify the best candidate, from those tested, for in vivo proof of concept studies in transgenic HD models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537 · cited 1×
“The selectivity of these antibodies may have crucial therapeutic advantages over the use of neurotrophins, given that the latter show an ability to also activate the ‘low affinity’ p75 receptor that is involved in neuronal cell death, representing an adverse ontarget effect [41].”
BackgroundInclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979 · cited 1×
“neuroprotective or neurotoxic effect [11,12].”
Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., & Wanker, E. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80514-0 · Cited by 1,291 · cited 1×
“mutant form of HTT misfolds and aggregates, which occurs concomitantly with disease progression [8,9].”
BackgroundNeurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406 · cited 4×
“Literature-reporteded TrkB small molecule agonists tested were amitriptyline [33], 7,8-dihydroxyflavone [36,37], N-acetyl serotonin [35], LM22A-4 [38], and BAG (cyclic peptide [39].”
BackgroundMethodInfluentialOchs, G., Penn, R. D., York, M., Giess, R., Beck, M., Tonn, J., Haigh, J., Malta, E., Traub, M., Sendtner, M., et al. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/14660820050515197 · Cited by 302 · cited 1×
“We surmised that intrathecal delivery of BDNF using pumps may not result in broad distribution throughout the striatal target area [40] and elected instead to pursue alternative modalities that would activate TrkB receptors in vivo, which included purported small molecule and functional antibody activators of the TrkB…”
BackgroundIbáñez, C. F., & Simi, A. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.03.007 · Cited by 238
BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice
Xie, Y., Hayden, M. R., & Xu, B. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1637-10.2010 · Cited by 236
Zuccato, C., Marullo, M., Conforti, P., MacDonald, M. E., Tartari, M., & Cattaneo, E. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00111.x · Cited by 231
Jang, S.-W., Liu, X., Chan, C.-B., Weinshenker, D., Hall, R. A., Xiao, G., & Ye, K. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.010 · Cited by 144
Cited by
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Neurotrophin signalling: novel insights into mechanisms and pathophysiology
Mitre, M., Mariga, A., & Chao, M. V. (2017) · Clinical Science · doi:10.1042/cs20160044 · Cited by 263
TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury
Wang, Y., Liang, J., Xu, B., Yang, J., Wu, Z., & Cheng, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122282 · Cited by 152
BDNF signaling during the lifetime of dendritic spines
Zagrebelsky, M., Tacke, C., & Korte, M. (2020) · Cell and Tissue Research · doi:10.1007/s00441-020-03226-5 · Cited by 147
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00017-8 · Cited by 122
Metadata
- Authors
- Todd, D., Gowers, I., Dowler, S. J., Wall, M. D., McAllister, G., Fischer, D. F., Dijkstra, S., Fratantoni, S. A., van de Bospoort, R., Veenman-Koepke, J., Flynn, G., Arjomand, J., Dominguez, C., Munoz-Sanjuan, I., Wityak, J., & Bard, J. A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-04
- Volume
- 9
- Issue
- 2
- Pages
- e87923
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2036966153
- Cited by
- 93
- References
- 13
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0087923
- The paper
- Todd, D., Gowers, I., Dowler, S. J., Wall, M. D., McAllister, G., Fischer, D. F., Dijkstra, S., Fratantoni, S. A., van de Bospoort, R., Veenman-Koepke, J., Flynn, G., Arjomand, J., Dominguez, C., Munoz-Sanjuan, I., Wityak, J., & Bard, J. A. (2014). A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0087923
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.